Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHGNASDAQ:CLNNNASDAQ:GANXNYSE:NEUE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHGBright Health Group$6.85+0.4%$6.77$4.94▼$82.40$54.68M0.9372,717 shs10,766 shsCLNNClene$4.12+0.5%$3.28$2.28▼$7.80$36.83M0.4989,806 shs42,160 shsGANXGain Therapeutics$1.79+5.9%$1.87$0.89▼$3.19$50.61M0.11296,006 shs184,964 shsNEUENeueHealth$6.83-0.4%$6.76$3.79▼$7.66$61.15M0.5520,297 shs21,428 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHGBright Health Group+0.44%+0.74%+1.48%+22.10%+33.01%CLNNClene+0.49%-2.60%+73.84%+16.38%-46.16%GANXGain Therapeutics+5.92%+4.68%-0.56%-14.35%+38.76%NEUENeueHealth-0.04%+0.57%+1.26%+2.25%+29.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHGBright Health GroupN/AN/AN/AN/AN/AN/AN/AN/ACLNNClene2.5103 of 5 stars3.63.00.00.00.62.50.6GANXGain Therapeutics1.739 of 5 stars3.63.00.00.00.60.00.6NEUENeueHealth1.5488 of 5 stars1.05.00.00.00.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHGBright Health Group 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00870.87% UpsideGANXGain Therapeutics 3.17Buy$8.20358.10% UpsideNEUENeueHealth 2.00Hold$7.002.56% UpsideCurrent Analyst Ratings BreakdownLatest BHG, NEUE, CLNN, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/28/2025GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHGBright Health Group$2.76B0.02N/AN/A($25.47) per share-0.27CLNNClene$340K108.82N/AN/A($1.06) per share-3.89GANXGain Therapeutics$50K1,072.21N/AN/A$0.28 per share6.39NEUENeueHealth$936.66M0.07N/AN/A($163.57) per share-0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHGBright Health Group-$1.46B-$208.73N/AN/AN/A-85.40%N/A-10.26%N/ACLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%-1,106.30%-105.11%8/6/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)NEUENeueHealth-$134.68M-$22.00N/AN/AN/A-14.28%-6.40%-17.46%8/6/2025 (Estimated)Latest BHG, NEUE, CLNN, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/8/2025Q1 2025NEUENeueHealth-$2.51-$1.80+$0.71-$2.90$249.50 million$215.79 million5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHGBright Health GroupN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ANEUENeueHealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHGBright Health GroupN/A1.041.04CLNNCleneN/A1.361.36GANXGain Therapeutics0.052.222.22NEUENeueHealthN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHGBright Health GroupN/ACLNNClene23.28%GANXGain Therapeutics11.97%NEUENeueHealth63.88%Insider OwnershipCompanyInsider OwnershipBHGBright Health Group58.40%CLNNClene35.30%GANXGain Therapeutics7.18%NEUENeueHealth63.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHGBright Health Group2,8407.98 million3.32 millionNot OptionableCLNNClene1008.98 million5.81 millionOptionableGANXGain Therapeutics2029.95 million27.80 millionOptionableNEUENeueHealth1,2528.93 million3.28 millionN/ABHG, NEUE, CLNN, and GANX HeadlinesRecent News About These CompaniesShort Interest in NeueHealth, Inc. (NYSE:NEUE) Drops By 39.7%June 16, 2025 | marketbeat.comElevation Point adds two execs to drive continued expansionJune 9, 2025 | investmentnews.comNeueHealth, Inc. (NYSE:NEUE) Short Interest UpdateJune 3, 2025 | marketbeat.comTwo other views on UnitedHealth Group’s annus horribilis, for your considerationJune 3, 2025 | telecareaware.comElevation Point bolsters board with Orion founding CEO Eric ClarkeJune 2, 2025 | investmentnews.comIndustry Leaders Eric Clarke and Mike Mikan Join Elevation Point's Board of DirectorsJune 2, 2025 | finance.yahoo.comNeueHealth (NYSE:NEUE) Trading Down 2% - What's Next?May 28, 2025 | marketbeat.comHow Bright Health went from insurtech darling to cautionary taleMay 21, 2025 | modernhealthcare.comAfter spinoff, 3M is no longer one of Minnesota’s five largest public companiesMay 15, 2025 | msn.comNeueHealth, Inc (NEUE) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comAbu Dhabi Grows Health Care Presence In San Francisco To Lure More StartupsMay 9, 2025 | kffhealthnews.orgNeueHealth to go private after shareholder voteMay 9, 2025 | modernhealthcare.comNeueHealth Inc (NEUE) Q1 2025 Earnings Call Highlights: Strong Consumer Growth and Continued ...May 9, 2025 | finance.yahoo.comNeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025April 23, 2025 | gurufocus.comNEUEHEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, ...April 16, 2025 | gurufocus.comNEUEHEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeueHealth, Inc. - NEUEApril 16, 2025 | businesswire.comJudge dismisses part of SSM Health-Bright Health lawsuitApril 1, 2025 | modernhealthcare.comNeueHealth, Inc. (NYSE:NEUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comQ4 2024 NeueHealth Inc Earnings CallMarch 21, 2025 | finance.yahoo.comNeueHealth, Inc (NEUE) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comNeueHealth: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHG, NEUE, CLNN, and GANX Company DescriptionsBright Health Group NYSE:BHG$6.85 +0.03 (+0.44%) As of 06/23/2025Bright Health Group, Inc., a healthcare company, provides health insurance policies in the United States. It operates in two segments, Bright HealthCare and Consumer Care. The Consumer Care segment delivers virtual and in-person clinical care services contracts through primary care clinics. It operates managed and affiliated risk-bearing clinics within its integrated care delivery system, which included embedded pharmacy, laboratory, radiology, and population health focused specialty services. The Bright HealthCare segment offers medicare health plan products to consumers. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is headquartered in Minneapolis, Minnesota.Clene NASDAQ:CLNN$4.12 +0.02 (+0.49%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$4.15 +0.03 (+0.73%) As of 06/24/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Gain Therapeutics NASDAQ:GANX$1.79 +0.10 (+5.92%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.87 +0.08 (+4.47%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.NeueHealth NYSE:NEUE$6.82 -0.03 (-0.36%) As of 06/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
